Regional variation in health state preferences Does it exist, and does it matter?

Similar documents
Discriminative validity of the EQ-5D-5 L and SF-12 in older adults with arthritis

Alberta PROMs & EQ-5D Research & Support Unit (APERSU): A Brief Introduction. Dr. Jeff Johnson January 30, 2016

Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan

Kelvin Chan Feb 10, 2015

To what extent do people prefer health states with higher values? A note on evidence from the EQ-5D valuation set

Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries

A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches

Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Questionnaire Health State Utility Values

Using Discrete Choice Experiments with duration to model EQ-5D-5L health state preferences: Testing experimental design strategies

Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets

A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes

University of Groningen

Economics of Frailty. Eamon O Shea

CDEC FINAL RECOMMENDATION

Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients

Initial Recommendation for Ibrutinib (Imbruvica) for Mantle Cell Lymphoma perc Meeting: June 16, pcodr PAN-CANADIAN ONCOLOGY DRUG REVIEW 4

The effect of systemic exposure to efavirenz, sex and age on the risk of virological nonsuppression in HIV-infected African children.

Mapping the Positive and Negative Syndrome Scale scores to EQ-5D- 5L and SF-6D utility scores in patients with schizophrenia

Small-area estimation of mental illness prevalence for schools

University of Bristol - Explore Bristol Research. Publisher's PDF, also known as Version of record

Japan Journal of Medicine

How is the most severe health state being valued by the general population?

Sample Sizes for Predictive Regression Models and Their Relationship to Correlation Coefficients

Ordinal Data Modeling

VALUE FRAMEWORKS IN HTA Are Value Frameworks Useful in Helping Canadian Cancer Systems Determine Funding for New Therapies?

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Statistical Considerations: Study Designs and Challenges in the Development and Validation of Cancer Biomarkers

pan-canadian Oncology Drug Review Final Economic Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes

This is a repository copy of Estimating an EQ-5D population value set: the case of Japan.

The Canadian Strategy for Cancer Control: Assessing Impact over the Last Decade. November 2, 2016

A Latent Variable Approach for the Construction of Continuous Health Indicators

Bayesian performance

Estimation of effect sizes in the presence of publication bias: a comparison of meta-analysis methods

Pharmacists in Canada A national survey of Canadians on their perceptions and attitudes towards pharmacists in Canada.

Mapping health outcome measures from a stroke registry to EQ-5D weights

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D

pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018

Waiting times. Deriving utility weights for the EQ-5D-5L

pan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Predictive statistical modelling approach to estimating TB burden. Sandra Alba, Ente Rood, Masja Straetemans and Mirjam Bakker

Choice of EQ 5D 3L for Economic Evaluation of Community Paramedicine Programs Project

OVERALL CLINICAL BENEFIT

Implementing BC s Influenza Prevention Policy

Food for thought. Department of Health Services Research 1

What Site Characteristics Explain Variability Of Peak Footing Drain Flows? Oskar Nordstrom, P.E. Mark TenBroek, P.E. CDM Michigan Inc.

Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument: The Potential to Estimate QALYs without Generic Preference Data

Assessment of Health State in Patients With Tinnitus: A Comparison of the EQ-5D and HUI Mark III

Measurement Models for Behavioral Frequencies: A Comparison Between Numerically and Vaguely Quantified Reports. September 2012 WORKING PAPER 10

THE COST OF DIABETES IN BRITISH COLUMBIA

Technical Appendix. Response to: Quality review of a proposed EEPRU review of the EQ-5D-5L value set for England

DEVICES AND TECHNOLOGY

Valuing health using visual analogue scales and rank data: does the visual analogue scale contain cardinal information?

EuroQol Working Paper Series

Online Supplementary Appendix

Experiences of trans women living with HIV in Canada: findings from a national community-based participatory research project

Published online: 10 January 2015 The Author(s) This article is published with open access at Springerlink.com

Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D

Patient Details Hidden. Clinical Enrollment. Quality of Life. EuroQOL (EQ-5D) Enroll Patient. Not Started. Not Started

Neuropathic pain (pain due to nerve damage)

Varicose Veins Surgery Questionnaire

Diabetes and Hypertension in Canada: New data from the Canadian Chronic Disease Surveillance System

& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and

pan-canadian Oncology Drug Review Final Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer January 4, 2019

The usefulness of EuroQol and McGill Quality of Life questionnaires in palliative care in-patients

Health Economics & Decision Science (HEDS) Discussion Paper Series

pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017

To what extent can we explain time trade-off values from other information about respondents?

Capability, Credibility, and Extended General Deterrence. Supplemental Material

Aliasghar A. Kiadaliri 1,2,6*, Björn Eliasson 3 and Ulf-G Gerdtham 4,5

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

How to Choose the Wrong Model. Scott L. Zeger Department of Biostatistics Johns Hopkins Bloomberg School

Catherine A. Welch 1*, Séverine Sabia 1,2, Eric Brunner 1, Mika Kivimäki 1 and Martin J. Shipley 1

Real World Cost-Effectiveness of Cancer Drugs

pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018

Organ Donation and Transplantation in Canada

Past Year Alcohol Consumption Patterns, Alcohol Problems and Alcohol-Related Diagnoses in the New Zealand Mental Health Survey

3 Cystic Fibrosis Clinic, University of Alberta Hospital, Edmonton, Alberta, Canada

The Impact of Cellphone Sample Representation on Variance Estimates in a Dual-Frame Telephone Survey

NICE DSU TECHNICAL SUPPORT DOCUMENT 8: AN INTRODUCTION TO THE MEASUREMENT AND VALUATION OF HEALTH FOR NICE SUBMISSIONS

pan-canadian Oncology Drug Review Initial Economic Guidance Report Inotuzumab Ozogamicin (Besponsa) for Acute Lymphoblastic Leukemia May 3, 2018

Time to tweak the TTO: results from a comparison of alternative specifications of the TTO

Health-related quality of life of adults living with HIV in England & Wales: a utility analysis of EQ-5D-5L compared to the general population

Reviewing Implementation Issues in Dialysis: Challenges and Opportunities. EFTYHIA HELIS, MSc KNOWLEDGE MOBILIZATION

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

An Introduction to Costeffectiveness

Issues for selection of outcome measures in stroke rehabilitation: ICF Participation

Valuation of EQ-5D Health States in Poland: First TTO-Based Social Value Set in Central and Eastern Europevhe_

THE RELATIONSHIP BETWEEN ACTIVITIES OF DAILY LIVING AND MULTIMORBIDITY. A VIEW FROM TELECARE

CADTH Canadian Drug Expert Committee Recommendation

Response shift or recall bias

Capture-recapture method for assessing publication bias

patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease

AN ESCALATING THYROID CANCER EPIDEMIC

CDEC FINAL RECOMMENDATION

Transcription:

Regional variation in health state preferences Does it exist, and does it matter? Eleanor Pullenayegum, on behalf of the Canadian EQ-5D-5L valuation team

Acknowledgements Canadian EQ-5D-5L Valuation Study Team PIs: Feng Xie & Jeffrey Johnson Co-Is: Stirling Bryan, Nick Bansback, Arto Ohinmaa, Lise Poissant Co-ordinator: Kathy Gaebel RAs: Samantha Pollard, Lidia Engel, Serena Humphries, Fatima Al Sayah, Touria Addou Practicum Student: Kelly Sunderland Funding from CIHR and EuroQol Foundation

Why bother asking? Health utilities used in decision-making should reflect preferences of the population who fund healthcare Between-country variability well established Canadian-specific utilities preferred BUT Decisions are made provincially Significant differences in demographics, culture and values among provinces If preferences vary among provinces, provincial utilities should be preferred

Does regional variation exist? Scoring algorithm Model mean TTO as a function of health state attributes Yields predicted mean utilities for those 3038 health states not directly valued Do provincial-specific algorithms fit better than the Canada-wide algorithm In terms of mean absolute error on cross-validation

Would a separate scoring algorithm for each province fit the National Scoring Algorithm data better? Number at level 4 or 5 beyond the 1st Intercept 1.1351 Mobility -0.0389 Self-care -0.0458 Usual Activities -0.0195 Pain/Discomfort -0.0444 Anxiety/Depression -0.0376 Mobility level 4 or worse -0.0510 Self-care level 4 or worse -0.0584 Usual Activities level 4 or worse -0.1103 Pain/Discomfort level 4 or worse -0.1409 Anxiety/Depression level 4 or worse -0.1277 Num45^2 0.0085 x2 x4 x2 Example: Utility for this state would be 1.1351 2*0.0389 0.0458 0.0195 4*0.0444 2*0.0376 0.1409 = 0.60

Does regional variation exist? Model stratified by province vs. Model ignoring province Incorporating provinces: Large improvement in AIC p<0.0001 for likelihood ratio test Improved goodness-of-fit Akaike Information Criterion (lower is better) Model AIC No region 10880 interactions Fully stratified 10787 Selected 10785 interactions

Do provincial algorithms fit better? Observed mean TTO utilities Provincial Predicted utilities: Provincial National Mean absolute Error (MAE) MAE provincial MAE national Province-specific scoring algorithms Use all data, not just provincespecific Computed using shrinkage Borrows strength across provinces Better mean-square error than provincial data alone

Usual Activities (level 4 or 5) -0.25-0.15-0.05 0.00 Pain/Discomfort (level 4 or 5) -0.20-0.15-0.10 Num45^2-0.01 0.00 0.01 0.02 Intercept 1.00 1.10 1.20 Self-care -0.07-0.05-0.03 Usual Activities -0.06-0.04-0.02 0.00 0.02 Pain/Discomfort -0.07-0.05-0.03 Regional Scoring Algorithms AB BC ON QC AB BC ON QC AB BC ON QC AB BC ON QC AB ON QC BC ON QC AB BC QC BC AB ON

Bland-Altman Plot Can one method of measurement replace another? Standard

Bland-Altman plots for health states BC utilities lower than national average Poor health states have lower utilities than national average in ON Better health states have higher utilities than national average in ON Poor health states have higher utilities than national average in QC

Does it matter? Large sample excessive power Detect differences that are not important In the HTA context, EQ-5D is used to calculate Mean utilities in selected populations Incremental mean utilities MID for EQ-5D-3L is in the range 0.03-0.08

Does it matter? (Simulation) Simulated health state distributions Probability of occupying each of the 3125 EQ-5D-5L health states Health states that are similar had similar probabilities Multivariate Normal with a probit transformation Simulated health states from a population of size 1000 Applied provincial and national scoring algorithms Compared mean & incremental mean utilities National vs. Provincial

Bland-Altman plots for mean utilities Always overestimate Very sick populations overestimate Mostly underestimate Healthy populations - underestimate

Bland-Altman plots for incremental mean utilities

Discussion Regional variation exists & is important Canadian 5L study was not intended to provide provincial algorithms Inadequate precision Single city per province Not all provinces included Pan-Canadian study would be expected to do better than province-specific studies Shrinkage analysis borrows strength across provinces Implications for HTA in Canada?